Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of Tislelizumab combined with concurrent
chemoradiotherapy in the treatment of cervical cancer patients with cervical mass > 4cm and
regional lymph node metastasis, paracervical invasion and regional lymph node metastasis,
stage IIIA, stage IIIB, and stage IVA. To provide a clinical reference for finding a safe and
effective individualized treatment plan to improve the survival prognosis of locally advanced
cervical cancer patients.